Skip to content

HEPION PHARMACEUTICALS, INC.: 10-Q filed 2014-05-15

What HEPION PHARMACEUTICALS, INC. reported in its quarterly report filed 2014-05-15 (fiscal Q3 2014): 17 published measures, 38 facts as tagged in accession 0001104659-14-039435.

This filing

Form
10-Q (quarterly report)
Filed
2014-05-15
Fiscal period
fiscal Q3 2014
Accession
0001104659-14-039435 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All HEPION PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2014-03-312,643,495USD
At 2013-06-3086,716USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2014-03-319,985,855USD
At 2013-06-30227,211USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2014-03-31-7,342,360USD
At 2013-06-30-140,495USD

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-07-01 to 2014-03-3115,847USD274
2013-05-15 to 2014-03-3115,847USD321

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2013-07-01 to 2014-03-310USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2014-03-3115,847USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-07-01 to 2014-03-31144,075USD274
2013-05-15 to 2014-03-31144,075USD321

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-458,970USD90
2013-07-01 to 2014-03-31-802,596USD274
2013-05-15 to 2014-03-31-942,764USD321

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2014-03-312,627,648USD
At 2013-06-3086,716USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2014-03-31259,864USD
At 2013-06-30227,211USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2014-03-31187,725USD
At 2013-06-303,617USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2014-01-01 to 2014-03-3172,507USD90
2013-07-01 to 2014-03-3195,353USD274
2013-05-15 to 2014-03-31113,094USD321

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2014-03-3118,479,279shares
At 2013-06-309,000,000shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2014-03-3166,665USD
At 2013-06-3040,000USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-9,311,759USD90
2013-07-01 to 2014-03-31-9,661,976USD274
2013-05-15 to 2014-03-31-9,802,471USD321
2013-05-15 to 2013-06-30-140,495USD47

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2014-01-01 to 2014-03-31386,463USD90
2013-07-01 to 2014-03-31707,243USD274
2013-05-15 to 2014-03-31829,670USD321

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2014-01-01 to 2014-03-31-8,852,789USD90
2013-07-01 to 2014-03-31-8,859,380USD274
2013-05-15 to 2014-03-31-8,859,707USD321

Inspect the source

Entity
HEPION PHARMACEUTICALS, INC. / CIK 0001583771
Captured
2026-09-20T09:23:01.444Z
SEC response SHA-256
8713b65a28b6abe1fe9df431214197b2d073688f1082552d43175ea3504e60ff

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001583771.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))